Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model

Proteomics

Volumn 9, Issue 8, 2009, Pages 2118-2130

  Aggelis, Vassilis ^a   Craven, Rachel A ^a   Peng, Jianhe ^a   Harnden, Patricia ^a   Cairns, David A ^a   Maher, Eamonn R ^b   Tonge, Robert ^c   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Membrane proteins; Renal cancer; SILAC; VHL

Indexed keywords

ALPHA3 INTEGRIN; BETA1 INTEGRIN; STABLE ISOTOPE;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEOMICS; VON HIPPEL LINDAU DISEASE;

ANTIGENS, CD; ANTIGENS, CD147; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; FETAL PROTEINS; GLYCOSYLATION; HUMANS; ISOTOPE LABELING; KIDNEY NEOPLASMS; MASS SPECTROMETRY; MEMBRANE PROTEINS; PROTEOMICS; TRANSFECTION; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 65349161457     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800756     Document Type: Article

References (73)

1. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Uchida, K., Miyao, N., Masumori, N., Takahashi, A. et al., Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int. J. Urol. 2002, 9, 19-23.
3. Fisher, R. I., Rosenberg, S. A., Fyfe, G., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 2000, 6 Suppl 1, S55-S57.
4. Messing, E. M., Manola, J., Wilding, G., Propert, K. et al., Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 2003, 21, 1214-1222.
5. Kaelin, W. G., Jr., The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 2007, 13, 680s-684s.
6. Latif, F., Tory, K., Gnarra, J., Yao, M. et al., Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260, 1317-1320.
7. Kaelin, W. G., Jr., The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 2004, 10, 6290S-6295S.
8. Banks, R. E., Tirukonda, P., Taylor, C., Hornigold, N. et al., Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006, 66, 2000-2011.
9. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C. et al., The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
10. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A. et al., Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2000, 2, 423-427.
11. Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M. et al., The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1998, 1, 959-968.
12. Devarajan, P., De Leon, M., Talasazan, F., Schoenfeld, A. R. et al., The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J. Biol. Chem. 2001, 276, 40599-40605.
13. Schoenfeld, A. R., Parris, T., Eisenberger, A., Davidowitz, E. J. et al., The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 2000, 19, 5851-5857.
14. Kuehn, E. W., Walz, G., Benzing, T., Von hippel-lindau: A tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res. 2007, 67, 4537-4540.
15. Kamada, M., Suzuki, K., Kato, Y., Okuda, H., Shuin, T., von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 2001, 61, 4184-4189.
16. Grandinetti, C. A., Goldspiel, B. R., Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007, 27, 1125-1144.
17. Feldman, D. R., Motzer, R. J., Novel targets and therapies for metastatic renal cell carcinoma. Oncology 2006, 20, 1745-1753.
18. Wykoff, C. C., Sotiriou, C., Cockman, M. E., Ratcliffe, P. J. et al., Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 2004, 90, 1235-1243.
19. Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R. et al., Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002, 62, 3803-3811.
20. Craven, R. A., Hanrahan, S., Totty, N., Harnden, P. et al., Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006, 6, 3880-3893.
21. Nakamura, E., Abreu-e-Lima, P., Awakura, Y., Inoue, T. et al., Clusterin is a secreted marker for a hypoxia-inducible factorindependent function of the von Hippel-Lindau tumor suppressor protein. Am. J. Pathol. 2006, 168, 574-584.
22. Hastie, C., Saxton, M., Akpan, A., Cramer, R. et al., Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 2005, 24, 5905-5913.
23. Shin, B. K., Wang, H., Yim, A. M., Le Naour, F. et al., Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 2003, 278, 7607-7616
24. Zhao, Y., Zhang, W., Kho, Y., Proteomic analysis of integral plasma membrane proteins. Anal. Chem. 2004, 76, 1817-1823.
25. Han, D. K., Eng, J., Zhou, H., Aebersold, R., Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nature Biotech. 2001, 19, 946-951.
26. Stockwin, L. H., Blonder, J., Bumke, M. A., Lucas, D. A. et al., Proteomic analysis of plasma membrane from hypoxiaadapted malignant melanoma. J. Prot. Res. 2006, 5, 2996-3007.
27. Pshezhetsky, A. V., Fedjaev, M., Ashmarina, L., Mazur, A. et al., Subcellular proteomics of cell differentiation: Quantitative analysis of the plasma membrane proteome of Caco-2 cells. Proteomics 2007, 7, 2201-2215.
28. Ong, S. E., Mann, M., Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol. Biol. Clifton, N. J 2007, 359, 37-52.
29. Liang, X., Zhao, J., Hajivandi, M., Wu, R. et al., Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J. Prot. Res. 2006, 5, 2632-2641.
30. Zhao, Y., Zhang, W., Kho, Y., Zhao, Y., Proteomic analysis of integral plasma membrane proteins. Anal. Chem. 2004, 76, 1817-1823.
31. Neuhoff, V., Arold, N., Taube, D., Ehrhardt, W., Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988, 9, 255-262.
32. Shilov, I. V., Seymour, S. L., Patel, A. A., Loboda, A. et al., The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 2007, 6, 1638-1655.
33. Guo, Y., Singleton, P. A., Rowshan, A., Gucek, M. et al., Quantitative proteomics analysis of human endothelial cell membrane rafts: Evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol. Cell. Proteomics 2007, 6, 689-696.
34. Rice, P., Longden, I., Bleasby, A., EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet. 2000, 16, 276-277
35. Fuhrman, S. A., Lasky, L. C., Limas, C., Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 1982, 6, 655-663.
36. TNM classification of malignant tumours (UICC) (April 2002), 6th Edition, Sobin, L. H., Wittekind, C. H (eds).
37. Banks, R. E., Craven, R. A., Harnden, P. A., Selby, P. J., Use of a sensitive EnVision +-based detection system for Western blotting: Avoidance of streptavidin binding to endogenous biotin and biotin-containing proteins in kidney and other tissues. Proteomics 2003, 3, 558-561.
38. Ferguson, R. E., Carroll, H. P., Harris, A., Maher, E. R. et al., Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 2005, 5, 566-571.
39. Alberghini, A., Recalcati, S., Tacchini, L., Santambrogio, P. et al., Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells. J. Biol. Chem. 2005, 280, 30120-30128.
40. Davidowitz, E. J., Schoenfeld, A. R., Burk, R. D., VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 2001, 21, 865-874.
41. Esteban-Barragan, M. A., Avila, P., Alvarez-Tejado, M., Gutierrez, M. et al., Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res. 2002, 62, 2929-2936.
42. Adam, P. J., Boyd, R., Tyson, K. L., Fletcher, G. C. et al., Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J. Biol. Chem. 2003, 278, 6482-6489.
43. Simpson, R. J., Connolly, L. M., Eddes, J. S., Pereira, J. J. et al., Proteomic analysis of the human colon carcinoma cell line (LIM 1215): Development of a membrane protein database. Electrophoresis 2000, 21, 1707-1732.
44. Sabarth, N., Lamer, S., Zimny-Arndt, U., Jungblut, P. R. et al., Identification of surface proteins of Helicobacter pylori by selective biotinylation, affinity purification, and two-dimensional gel electrophoresis. J. Biol. Chem. 2002, 277, 27896-27902.
45. Jang, J. H., Hanash, S., Profiling of the cell surface proteome. Proteomics 2003, 3, 1947-1954.
46. Mlynarek, A. M., Balys, R. L., Su, J., Hier, M. P. et al., A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133, 910-918.
47. Springer, D. L., Ahram, M., Adkins, J. N., Kathmann, L. E., Miller, J. H., Characterization of medium conditioned by irradiated cells using proteome-wide, high-throughput mass spectrometry. Radiation Res. 2005, 164, 651-654.
48. Chevallet, M., Diemer, H., Van Dorssealer, A., Villiers, C., Rabilloud, T., Toward a better analysis of secreted proteins: The example of the myeloid cells secretome. Proteomics 2007, 7, 1757-1770.
49. Ofori-Acquah, S. F., King, J. A., Activated leukocyte cell adhesion molecule: A new paradox in cancer. Transl. Res. 2008, 151, 122-128.
50. Jezierska, A., Matysiak, W., Motyl, T., ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med. Sci. Monit. 2006, 12, BR263-BR273.
51. Swart, G. W., Lunter, P. C., Kilsdonk, J. W., Kempen, L. C., Activated leukocyte cell adhesion molecule (ALCAM/ CD166): Signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 2005, 24, 223-236.
52. Nelissen, J. M., Peters, I. M., de Grooth, B. G., van Kooyk, Y., Figdor, C. G., Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol. Biol. Cell. 2000, 11, 2057-2068.
53. Hofmann, U. B., Westphal, J. R., Zendman, A. J., Becker, J. C. et al., Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Path. 2000, 191, 245-256.
54. Lunter, P. C., van Kilsdonk, J. W., van Beek, H., Cornelissen, I. M. et al., Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 2005, 65, 8801-8808.
55. Petrella, B. L., Lohi, J., Brinckerhoff, C. E., Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005, 24, 1043-1052.
56. Struckmann, K., Mertz, K., Steu, S., Storz, M. et al., pVHL coordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J. Path. 2008, 214, 464-471.
57. Riethdorf, S., Reimers, N., Assmann, V., Kornfeld, J. W. et al., High incidence of EMMPRIN expression in human tumors. Int. J. Cancer 2006, 119, 1800-1810.
58. Jin, J. S., Hsieh, D. S., Lin, Y. F., Wang, J. Y. et al., Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Int. J. Urol. 2006, 13, 573-580.
59. Tsai, W. C., Sheu, L. F., Nieh, S., Yu, C. P. et al., Association of EMMPRIN and fascin expression in renal cell carcinoma: Correlation with clinicopathological parameters. World J. Urol. 2007, 25, 73-80.
60. Biswas, C., Zhang, Y., DeCastro, R., Guo, H. et al., The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55, 434-439.
61. Yan, L., Zucker, S., Toole, B. P., Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 2005, 93, 199-204.
62. Nabeshima, K., Iwasaki, H., Koga, K., Hojo, H. et al., Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathology Int. 2006, 56, 359-367.
63. Caudroy, S., Polette, M., Tournier, J. M., Burlet, H. et al., Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J. Histochem. Cytochem. 1999, 47, 1575-1580.
64. Polette, M., Gilles, C., Marchand, V., Lorenzato, M. et al., Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J. Histochem. Cytochem. 1997, 45, 703-709.
65. Bordador, L. C., Li, X., Toole, B., Chen, B. et al., Expression of emmprin by oral squamous cell carcinoma. Int. J. Cancer 2000, 85, 347-352.
66. Kanekura, T., Chen, X., Kanzaki, T., Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 2002, 99, 520-528.
67. Zucker, S., Hymowitz, M., Rollo, E. E., Mann, R. et al., Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol. 2001, 158, 1921-1928.
68. Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F. et al., Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65, 3193-3199.
69. Marieb, E. A., Zoltan-Jones, A., Li, R., Misra, S. et al., Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004, 64, 1229-1232.
70. Misra, S., Ghatak, S., Zoltan-Jones, A., Toole, B. P., Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 2003, 278, 25285-25288.
71. Yang, J. M., Xu, Z., Wu, H., Zhu, H. et al., Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol. Cancer Res. 2003, 1, 420-427.
72. Menashi, S., Serova, M., Ma, L., Vignot, S. et al., Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 2003, 63, 7575-7580.
73. Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N. et al., Hypoxia inducible factor activates the transforming growth factor-a/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 2003, 278, 44966-44974.